SC75741 is a potent P65 inhibitor with IC50 of 200 nM

NF-κB:200 nM(EC50)

SC75741 shows immunosuppressive activity by inhibiting human PBMC proliferation with IC50 of 2.2 μM. [1] SC75741 inhibits replication of influenza A and B viruses by inhibiting NF-κB-mediated signalling on a transcriptional level. Moreover, SC75741 shows a high barrier for development of resistant virus variants. [2]

SC75741 (15 mg/kg i.p.) reduces virus replication and cytokine expression in mice lungs after H5N1 influenza virus infection. [2]

NF-κB reporter gene assay: The NF-κB reporter gene assay is prepared with A549-NF-κB-SEAP cell line according to manufacturer's instructions. In short, A549 cells stably transfected with pNF-κB-SEAP reporter gene plasmid are plated and allowed to attach overnight. The cells are subsequently incubated for 5 h with described compounds at 100, 30, 10, 3, 1, 0.3, 0.1, and 0 μM and then stimulated with 10 ng/ml TNF-α for 22 h. The supernatant of the cell is analyzed for SEAP activity using a chemiluminescent SEAP reporter gene assay.

Cell viability assay is prepared using a CellTiter-BluTM Cell Viability Assay. For each concentration of the compound four replicates are measured.(Only for Reference)